唑来膦酸联合培美曲塞方案治疗非小细胞肺癌骨转移疗效研究

目的观察唑来膦酸联合培美曲塞治疗非小细胞肺癌（NSCLC）骨转移的疗效。方法 60例NSCLC骨转移患者,随机分为两组,分别为唑来膦酸组30例,对照组30例。唑来膦酸组接受唑来膦酸联合培美曲塞方案化疗,对照组为单纯培美曲塞方案化疗。结果两组肺部原发病灶有效率,唑来膦酸组有效率（CR＋PR）16.7%,疾病控制率（CR＋PR＋SD）60.0%;对照组有效率（CR＋PR）13.3%,疾病控制率（CR＋PR＋SD）53.3%。总体平均生存期7.5个月（2～17个月）,中位生存期唑来膦酸组7个月,对照组6个月。骨病灶控制唑来膦酸组的有效率（CR＋PR）40.0%,控制率（CR＋PR＋NC）83.3%,而对照组有效率13.3%,控制率36.7%。差异有显著性（P〈0.05）。骨转移疼痛缓解率唑来膦酸组79.2%,对照组45.8%。有显著性差异（P〈0.05）。结论唑来膦酸联合培美曲塞方案化疗对NSCLC骨转移不仅有较好的止痛作用,而且提高化疗疗效,是一种较佳的值得推广的临床选择方案。

Study on Zoledronic acid combined with pemetrexed in the treatment of Advanced non-small cell lung cancer with bone metastasis

Aim Observation the efficacy of zoledronic acid combined with pemetrexed in treatment of non-small cell lung cancer （NSCLC） with bone metastasis.Methods 60 cases of NSCLC patients with bone metastases were randomly divided into two groups,namely the zoledronic acid group of 30 patients in control group 30 cases.Zoledronic acid group received zoledronic acid combined with pemetrexed chemotherapy,and the control group was received simply pemetrexed chemotherapy.Results The control Efficient of Lung lesions Zoledronic acid group：（CR＋PR）16.7%,（CR＋PR＋SD）60.0%;control group： （CR＋PR）13.3%,（CR＋PR＋SD）53.3%;The overall average survival period was 7.5 months （2~17 months）,with a median survival time zoledronic acid group of 7 months and 6 months in the control group.Control of bone lesions： Zoledronic acid group：（CR＋PR）40.0%,（CR＋PR＋SD）83.3%;control group： （CR＋PR）13.3%,（CR＋PR＋SD）36.7%（P0.05）.The rate of bone metastasis pain relief zoledronic acid group 79.2%,control group 45.8%（P0.05）.Conclusion Zoledronic acid combined with pemetrexed chemotherapy for NSCLC with bone metastasis have a good treatment effect,Not only has good analgesic effect,but also to improve chemotherapy efficacy,it mabe a better option that can be widely used.